Orris

What’s new in cicatricial alopecia? I need to see a comment in a journal club as an audience.

Reading File
Reading File
Searching PubMed

"cicatricial alopecia"[MeSH Terms] AND treatment

Searching PubMed

"frontal fibrosing alopecia" AND "lichen planopilaris"

Searching the Web

cicatricial alopecia new treatment 2025 2026 JAK inhibitor update

Searching PubMed

ritlecitinib AND cicatricial alopecia

Reading Article

PMID: 39699852

Reading Web Page

https://www.medscape.com/viewarticle/jak3-tec-inhibitor-show…

What's new in cicatricial alopecia (2024-2026)

Headline development: JAK inhibitors are finally being tested in scarring alopecia. The most talked-about news is data on ritlecitinib (a JAK3/TEC inhibitor already approved for alopecia areata), presented as a late-breaking study at EADV 2025. It's one of the first systematic evaluations of a JAK inhibitor across multiple cicatricial alopecia subtypes at once.
  • Single-arm, open-label study, 50 patients across CCCA (n=20), FFA (n=15), and LPP (n=15) - conditions with no currently approved treatment.
  • Dosing: 200 mg/day x8 weeks, then tapered to 100 mg/day.
  • Primary endpoint was change in inflammatory biomarkers (paired lesional/nonlesional biopsies at baseline, 8, and 24 weeks); clinical improvement and safety were secondary.
  • Substantial downregulation of inflammatory gene signatures by 8 weeks in all three groups; the most robust immune downregulation was in CCCA (IL2RA/IL2RB, CCL13/CCL22, IL23R, S100A12).
  • Clinical improvement was often rapid; no serious adverse events and importantly no thrombosis/VTE signal (a class concern with other JAKs).
  • Trend (not significant, P=.164) toward better 48-week outcomes in patients with disease duration under ~3.5 years, reinforcing the "treat early" message. (via Medscape coverage of the EADV 2025 presentation)
Separately, Alopecia UK's 2026 research update notes a JAK inhibitor has now progressed to a phase 2b/3 trial specifically for lichen planopilaris - the first scarring-alopecia program to reach that stage.
FFA mechanism/epidemiology update - Messenger et al., Am J Clin Dermatol 2025 (PMID: 39699852):
  • Inherited predisposition to FFA is now genetically confirmed, not just suspected from familial clustering.
  • Environmental culprits under scrutiny remain facial moisturizers/UV filters and exogenous estrogen exposure, but no proven causal link yet.
  • Mechanistic clarifications: loss of follicular immune privilege at the bulge, epithelial-mesenchymal transition driving fibrosis.
  • Lichen planus pigmentosus is increasingly viewed as the same disease process on interfollicular skin rather than a separate comorbidity.
  • Treatment is still built mostly on retrospective case series with inconsistent endpoints - RCTs of JAK inhibitors are "in progress," which is exactly what the ritlecitinib data above represents.
CCCA-specific advances (non-JAK):
  • Topical metformin 10% cream as an adjuvant in recalcitrant CCCA - promising in case reports/small series (PMID: 40190490, 38923417).
  • Low-level light therapy (LLLT) as a novel CCCA treatment - interventional cohort study, 2026 (PMID: 40976525).
  • Doxycycline retrospective analysis for CCCA (PMID: 38458568).
  • An editorial in JAAD explicitly framed 2025 as a call to "improve outcomes" for CCCA patients (PMID: 40058603), reflecting how much unmet need remains.
Other 2024-2025 syntheses worth name-dropping:
  • Systematic review of procedural modalities (lasers, LLLT) for LPP/FFA/discoid lupus, 2025 (PMID: 41081974).
  • First systematic review of pediatric LPP, 2025 (PMID: 39629624).
  • Systematic review linking early diagnosis/treatment to better quality-of-life outcomes in LPP (PMID: 39152785) - useful if the journal club discusses patient-reported outcomes.

A ready comment you could raise as an audience member

"What strikes me most about this area right now is that we're moving from 'no approved therapy, treat empirically with steroids/antimalarials/doxycycline' toward a genuine JAK-inhibitor pipeline - ritlecitinib data at EADV 2025 showed rapid biomarker and clinical response across CCCA, FFA, and LPP with no thrombosis signal, and there's now a phase 2b/3 trial specifically for LPP. But it's worth flagging that the ritlecitinib study was open-label with no control arm and used a biomarker primary endpoint rather than a validated clinical scarring-alopecia score, so we still can't say how durable the hair regrowth is or how it'll compare head-to-head with, say, low-dose doxycycline or topical metformin for CCCA. The recurring theme across all these papers - Messenger's FFA update included - is that earlier intervention (here, under ~3.5 years of disease) trends toward better response, which argues for earlier biopsy and referral rather than watching-and-waiting once scarring starts."
That gives you a substantive, evidence-anchored talking point plus a built-in critical-appraisal angle (open-label design, surrogate endpoint, lack of comparator) that journal clubs usually reward.
Recency check: I did not find a Cochrane/major meta-analysis update specifically contradicting these findings in the last 2 years; the strongest recent systematic reviews (PMID: 41081974, 39629624, 39152785) are procedural/pediatric/QoL-focused rather than head-to-head drug trials, so the ritlecitinib phase 2b/3 data (not yet published) remains the thing to watch for updates.

More of clincopathological kind of comment i want

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.